qHTS to Identify Inhibitors of the Arf GTPase-activating Protein ASAP1
qHTS 鉴定 Arf GTP 酶激活蛋白 ASAP1 的抑制剂
基本信息
- 批准号:9551895
- 负责人:
- 金额:$ 13.57万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:Adaptor Signaling ProteinAntineoplastic AgentsBiological AssayBiologyChemicalsCollaborationsColorectal CancerCommunitiesDevelopmentDiseaseExtramural ActivitiesFosteringGTPase-Activating ProteinsGeneral PopulationGenomicsGoalsHumanInformaticsLeadLinkModelingPharmaceutical ChemistryPharmaceutical PreparationsPhenotypeProcessPublicationsResearchResearch PersonnelResourcesSynthesis ChemistryUnited States National Institutes of HealthValidationWorkassay developmentbasedrug developmentdrug discoveryhigh throughput screeninghuman diseaseimprovedinhibitor/antagonistnew technologynovelnovel therapeuticsscreeningsmall moleculesmall molecule inhibitorsmall molecule therapeuticstherapeutic developmenttooltumortumor progression
项目摘要
During this period, the NCGC has worked to adapt and optimize an HTS-amenable ASAP1 assay to enable high-throughput screening.
As a center, the NCGC has fostered and maintained over 130 active collaborations with both NIH and extramural investigators, facilitating drug discovery efforts across the entire spectrum of human disease. These efforts have led to dozens of high-throughput screens and a number of medicinal chemistry campaigns to further improve on screening hits, providing our collaborators and the general research community with publications and a variety of promising small molecule probes and leads. In addition, the NCGC has worked to advance a number of informatic initiatives to make better use of existing drug and disease target information and provide the general public with easily accessible resources, further catalyzing the development of new therapies for human disease.
在此期间,NCGC一直致力于调整和优化适用于hts的ASAP1检测,以实现高通量筛选。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Matthew Hall其他文献
Matthew Hall的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Matthew Hall', 18)}}的其他基金
BRD4 Inhibitors as Potential Therapeutics for Oncology
BRD4 抑制剂作为肿瘤学的潜在治疗药物
- 批准号:
9551899 - 财政年份:
- 资助金额:
$ 13.57万 - 项目类别:
qHTS to Identify Inhibitors of Mutant and Wildtype NSD2
qHTS 鉴定突变型和野生型 NSD2 抑制剂
- 批准号:
9359919 - 财政年份:
- 资助金额:
$ 13.57万 - 项目类别:
qHTS to Identify Activators and Inhibitors of Wip1
qHTS 鉴定 Wip1 激活剂和抑制剂
- 批准号:
9551889 - 财政年份:
- 资助金额:
$ 13.57万 - 项目类别:
qHTS to Identify Inducers of Oligodendrocyte-precursor cell (OPC) Remyelination
qHTS 鉴定少突胶质细胞前体细胞 (OPC) 髓鞘再生诱导剂
- 批准号:
9205679 - 财政年份:
- 资助金额:
$ 13.57万 - 项目类别:
qHTS to Identify Compounds against Merkel Cell Carcinoma (MCC)
qHTS 鉴定抗默克尔细胞癌 (MCC) 的化合物
- 批准号:
9553320 - 财政年份:
- 资助金额:
$ 13.57万 - 项目类别:
Development of small molecule modulators of WDR5/MLL1 protein-protein binding (Chemical Biology Consortium/NCI Experimental Therapeutics Collaboration)
开发 WDR5/MLL1 蛋白质-蛋白质结合的小分子调节剂(化学生物学联盟/NCI 实验治疗合作组织)
- 批准号:
9551927 - 财政年份:
- 资助金额:
$ 13.57万 - 项目类别:
qHTS to Identify Inhibitors of the Arf GTPase-activating Protein ASAP1
qHTS 鉴定 Arf GTP 酶激活蛋白 ASAP1 的抑制剂
- 批准号:
9359872 - 财政年份:
- 资助金额:
$ 13.57万 - 项目类别:
Canvass: revitalizing and advancing the translation of natural products research
游说:振兴和推进天然产物研究的转化
- 批准号:
10001307 - 财政年份:
- 资助金额:
$ 13.57万 - 项目类别:
相似海外基金
Delays in Acquisition of Oral Antineoplastic Agents
口服抗肿瘤药物的获取延迟
- 批准号:
9975367 - 财政年份:2020
- 资助金额:
$ 13.57万 - 项目类别:
Eliminate the difficulty of venous puncture in patients receiving antineoplastic agents - Development of a new strategy for the prevention of induration-
消除接受抗肿瘤药物的患者静脉穿刺的困难 - 制定预防硬结的新策略 -
- 批准号:
16K11932 - 财政年份:2016
- 资助金额:
$ 13.57万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular mechanisms of the antineoplastic agents inhibiting DNA replication and their applications to cancer patient treatmen
抗肿瘤药物抑制DNA复制的分子机制及其在癌症患者治疗中的应用
- 批准号:
19591274 - 财政年份:2007
- 资助金额:
$ 13.57万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
PNET EXPERIMENTAL THERAPEUTICS--ANTINEOPLASTIC AGENTS AND TREATMENT DELIVERY
PNET 实验治疗——抗肿瘤药物和治疗实施
- 批准号:
6346309 - 财政年份:2000
- 资助金额:
$ 13.57万 - 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
- 批准号:
2885074 - 财政年份:1999
- 资助金额:
$ 13.57万 - 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
- 批准号:
6174221 - 财政年份:1999
- 资助金额:
$ 13.57万 - 项目类别:














{{item.name}}会员




